<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703922</url>
  </required_header>
  <id_info>
    <org_study_id>ECHORTON</org_study_id>
    <nct_id>NCT02703922</nct_id>
  </id_info>
  <brief_title>Validation of a Diagnostic Algorithm of Giant Cell Arteritis</brief_title>
  <acronym>ECHORTON</acronym>
  <official_title>Validation d'un Algorithme Diagnostique de l'artérite Temporale Giganto-cellulaire basé Sur l'échographie-doppler Couleur Des artères Temporales Superficielles et Des Axes Cervico-encéphaliques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier de la Rochelle Ré Aunis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Rochefort</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant cell arteritis (GCA or temporal arteritis or cranial arteritis) or Horton disease is a
      vasculitis that occurs in older adults, affecting vessels of medium and large caliber. The
      diagnosis of GCA is a challenge for general practitioners and specialists. Since 1970, it is
      based on a combination of clinical, biological and histological signs. Temporal artery biopsy
      (TAB) was the reference method until recently. However, TAB has many drawbacks. Therefore,
      researches of the past 20 years have been intended to develop alternative diagnostic methods.
      This was notably the case of the color Doppler ultrasound (CDU) since the description by
      Wolfgang Schmidt of the halo sign. Although European and British recommendations put CDU as
      second line method, many authors suggest the possibility to do without TAB in many cases. In
      addition, many practitioners believe that it is not &quot;ethical&quot; to use an invasive unprofitable
      procedure like TAB, and have already been using CDU in their routine practice. However, no
      diagnostic algorithm validating this approach in a prospective series has been published to
      date. Therefore, the present study aim at validating a diagnostic algorithm of giant cell
      arteritis using color Doppler imaging of temporal arteries and cervicocephalic axes as first
      screening method.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2016</start_date>
  <completion_date type="Anticipated">September 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CDU false-positive patients</measure>
    <time_frame>after 2 years of follow-up</time_frame>
    <description>patients with an alternative diagnosis within 2 years of follow-up among patients considered with GCA on a clinico-biological suspicion + Doppler &quot;positive.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of &quot;TAB positive&quot; among &quot;negative or doubtful CDU &quot;</measure>
    <time_frame>within 1 month (during diagnostic algorithm)</time_frame>
    <description>Number of TAB positive patients per patients with negative or doubtful CDU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a persistent Halo at second CDU examination</measure>
    <time_frame>after 2 years of follow-up</time_frame>
    <description>Describe S3/S4 Halo changes, and study correlation between persistence and poorer clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of correctly interpreted TAB</measure>
    <time_frame>1 month (after second blind reading of histological specimen and doppler imaging)</time_frame>
    <description>Reproducibility of TAB interpretation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of correctly interpreted CDU</measure>
    <time_frame>1 month (after second blind reading of histological specimen and doppler imaging)</time_frame>
    <description>Reproducibility of CDU interpretation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-result of the algorithm</measure>
    <time_frame>after 2 years of follow-up</time_frame>
    <description>Diagnostic costs, induced costs, avoided costs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>GCA suspicion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>color Doppler ultrasound and TAB in case of CDU negative</intervention_name>
    <description>Screening with color Doppler ultrasound followed by TAB in case of CDU negative</description>
    <arm_group_label>GCA suspicion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 50 years

          -  C reactive protein (CRP) above normal

          -  Suspected of GCA according to clinician expertise and / or aortitis arteritis or of
             one or more arteries from the aorta imaging (CT angiography, magnetic resonance
             angiography or positron emission tomography TDM18FDG)

          -  Benefiting from Social Security or receiving it via a third party

          -  have given their participation agreement by understanding and accepting the
             constraints of the study

        Exclusion Criteria:

          -  Received corticosteroid dose ≥ 20 mg of prednisone equivalent for more than 7 days in
             the month before inclusion

          -  Underwent temporal artery biopsy before color Doppler ultrasound

          -  History of GCA

          -  Terminal palliative phase or suffering from a disease or comorbidities such as life is
             involved in less than a year

          -  Patient with severe cognitive impairment

          -  Patient that can not be followed by the investigator for the duration of the study

          -  Refusal to participate in the study

          -  With enhanced protection (namely those deprived of liberty by a court or
             administrative order, patient staying in a health or social institution, under legal
             protection, and patients in emergencies)

          -  Pregnant or breastfeeding women, women of childbearing age who do not have effective
             contraception

          -  Participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Roncato, MD</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Hospitalier de la Rochelle Ré Aunis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume Denis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier de Rochefort</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Allix-Béguec, Ph.D.</last_name>
    <phone>+33516494246</phone>
    <email>caroline.allix-beguec@ch-larochelle.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier d'Angoulême</name>
      <address>
        <city>Angoulême</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes RICHE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier de la Rochelle Ré Aunis</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Renaud</last_name>
      <phone>+33516494245</phone>
      <email>karen.renaud-geffard@ch-larochelle.fr</email>
    </contact>
    <investigator>
      <last_name>Mariam Saberan-Roncato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Gombert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaëlle Godenèche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Grossin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Brottier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lydia Faba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Pouget-Abadie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Niort</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Dezaux</last_name>
      <email>marjorie.dezaux@ch-niort.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Blanchard-Delaunay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Lormeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Abriat</last_name>
      <phone>+33549443796</phone>
      <email>fanny.abriat@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric Landron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Solau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine Durand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rochefort</name>
      <address>
        <city>Rochefort</city>
        <zip>17301</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Denis, MD</last_name>
      <phone>+33546885600</phone>
      <email>guillaume.denis@ch-rochefort.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume Denis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline Dieval, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014 Oct 23;371(17):1653. doi: 10.1056/NEJMc1409206.</citation>
    <PMID>25337759</PMID>
  </reference>
  <reference>
    <citation>Smith JH, Swanson JW. Giant cell arteritis. Headache. 2014 Sep;54(8):1273-89. doi: 10.1111/head.12425. Epub 2014 Jul 18. Review.</citation>
    <PMID>25041449</PMID>
  </reference>
  <reference>
    <citation>Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken). 2015 Mar;67(3):390-5. doi: 10.1002/acr.22429.</citation>
    <PMID>25132663</PMID>
  </reference>
  <reference>
    <citation>Calvo-Romero JM. Giant cell arteritis. Postgrad Med J. 2003 Sep;79(935):511-5. Review.</citation>
    <PMID>13679546</PMID>
  </reference>
  <reference>
    <citation>Roblot P. [When should Horton's disease be suspected?]. Rev Prat. 1999 Mar 15;49(6):593-7. French.</citation>
    <PMID>10218393</PMID>
  </reference>
  <reference>
    <citation>Baslund B, Helleberg M, Faurschou M, Obel N. Mortality in patients with giant cell arteritis. Rheumatology (Oxford). 2015 Jan;54(1):139-43. doi: 10.1093/rheumatology/keu303. Epub 2014 Aug 13.</citation>
    <PMID>25122725</PMID>
  </reference>
  <reference>
    <citation>Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003 Dec;48(12):3532-7.</citation>
    <PMID>14674005</PMID>
  </reference>
  <reference>
    <citation>Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013 Dec;72(12):1989-94. doi: 10.1136/annrheumdis-2012-202408. Epub 2012 Dec 19.</citation>
    <PMID>23253927</PMID>
  </reference>
  <reference>
    <citation>Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 Aug;33(8):1122-8.</citation>
    <PMID>2202311</PMID>
  </reference>
  <reference>
    <citation>Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc. 2006 Aug;81(8):1071-83.</citation>
    <PMID>16901030</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

